Agilent and Visiopharm Expand Collaboration with Worldwide Distribution Agreement
September 02 2021 - 8:00AM
Business Wire
Agilent Technologies Inc. (NYSE: A) today announced the signing
of a worldwide distribution agreement with Visiopharm, enabling
Agilent to co-market Visiopharm’s portfolio of CE-IVD marked
artificial intelligence (AI)-driven precision pathology software in
addition to Agilent’s portfolio of automated pathology staining
solutions. With an initial focus on Europe, this agreement marks
Agilent's first entry into the growing digital pathology market and
strengthens the relationship between the two companies by further
expanding the scope of their long-term collaboration.
Digital pathology is experiencing rapid growth worldwide, with
its adoption expected to double by the end of this decade. As the
use of digital pathology increases, AI-driven pathology solutions
are emerging as the new standard. These solutions can provide
diagnostic decision support and productivity enhancements that
enable pathologists to improve diagnostic accuracy and workload
management.
This adoption has been accelerated by the COVID-19 pandemic,
which has found pathologists increasingly reviewing cases remotely.
In the United Kingdom, for example, pathologists have received
guidance for remote reporting of digital pathology slides in times
of exceptional service pressure and support in the adoption of
technologies, such as digital pathology, that have the potential to
aid in their assessment.
“This is an exciting next step in our partnership with
Visiopharm,” said Lou Welebob, vice president and general manager
of Agilent’s Pathology Division. “Being able to offer our customers
digital pathology software alongside our range of automated
staining solutions is a powerful combination that can support
pathologists in their assessment and help improve patient care. We
look forward to our continued collaboration with Visiopharm as we
work together toward the fully digitalized pathology lab of the
future.”
Michael Grunkin, CEO, Visiopharm said: “We're delighted to
further expand our partnership with Agilent. With strong
complementary solutions, we will be able to address recognized and
currently unmet needs for both standardization and automation. This
distribution agreement is a logical first step towards supporting
those labs who share our joint vision of automated AI-driven
precision pathology."
Prior to this announcement, Agilent and Visiopharm have
collaborated to validate Visiopharm’s existing HER2 APP to include
Agilent’s new HercepTest™ mAb pharmDx for Dako Omnis, both CE-IVD
marked and available for sale in Europe. Released in October 2020,
this product enables pathologists to use the Visiopharm HER2 APP
for objective decision support in the assessment of HercepTest™ mAb
pharmDx stained slides, saving valuable time for both pathologists
and patients.
For in vitro diagnostic use in Europe.
HercepTest™ mAb pharmDx (Dako Omnis) (Code GE001):
The licensed antibody is created by Epitomics Inc. (an Abcam
company), using Abcam’s proprietary rabbit monoclonal antibody
technology covered under Patent No’s 5,675,063 and 7,402,409.
HercepTest™ and Herceptin® are trademarks owned by Genentech,
Inc.
About Agilent Technologies
Agilent is a leader in life sciences, diagnostics, and applied
chemical markets, delivering innovative technology solutions that
provide trusted answers to researchers’ most challenging scientific
questions. The company generated revenue of $5.34 billion in fiscal
year 2020 and employs 16,400 people worldwide. Information about
Agilent is available at www.agilent.com. To receive the latest
Agilent news, please subscribe to the Agilent Newsroom. Follow
Agilent on LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210902005423/en/
Media Contact Naomi Goumillout Agilent Technologies
+1.781.266.2819 naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024